DrugPatentWatch Database Preview
Details for Patent: 9,192,616
Which drugs does patent 9,192,616 protect, and when does it expire?
This patent has thirty-four patent family members in eleven countries.
Summary for Patent: 9,192,616
Title: | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Abstract: | A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication in the container when taken with food. |
Inventor(s): | Johnson; Lorin (Palo Alto, CA) |
Assignee: | Salix Pharmaceuticals, Inc. (Raleigh, NC) |
Application Number: | 13/439,594 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 9,192,616
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Valeant Pharms Intl | GIAZO | balsalazide disodium | TABLET;ORAL | 022205-001 | Feb 3, 2012 | AB | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS | ➤ Try a Free Trial | |||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 9,192,616
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,921,344 | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives | ➤ Try a Free Trial |
7,452,872 | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives | ➤ Try a Free Trial |
7,625,884 | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives | ➤ Try a Free Trial |
Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 9,192,616
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2006282865 | ➤ Try a Free Trial | |||
Australia | 2007322362 | ➤ Try a Free Trial | |||
Brazil | PI0615195 | ➤ Try a Free Trial | |||
Brazil | PI0717859 | ➤ Try a Free Trial | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |